APL-101 (c-METi)

APL-101: c-Met inhibitor

APL-101 is a novel, highly selective small molecule c-Met inhibitor (c-METi) that targets the c-Met-dysregulated pathway in several tumors. APL-101 has demonstrated tumor inhibitory effect in a variety of human primary gastric, hepatic, pancreatic and lung tumor xenograft animal models with c-Met dysregulations.

c-Met, which is also known as the hepatocyte growth factor receptor, or HGFR, is a signaling receptor tyrosine kinase that has specific roles in normal mammalian growth and development. However, the c-Met pathway has also been shown to function abnormally in a range of different cancers through c-Met gene amplification, over-expression, and gene mutations, deletions, and insertions. The abnormal activation of c-Met has been demonstrated in many cancer including kidney, lung, gastric, colorectal, esophageal and brain cancer.  Dysregulated c-Met plays a major role in cancer development including tumor growth, survival, invasions, and metastasis.

APL-101 has demonstrated tumor inhibitory effect in a variety of human primary gastric, hepatic, pancreatic and lung tumor xenograft animal models with c-Met dysregulations.

Apollomics retains worldwide rights to APL-101 outside of China.

Clinical Trials

APL-101 is currently being evaluated in several ongoing clinical trials.  For additional information, please click on the trial links below.

Apollomics Sparta

Sparta Phase 2 Clinical Trial
An international multicenter, open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of APL-101.
Trial: NCT03175224

Target Indications:

  • Non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations
  • Glioblastoma multiforme with MET amplifications and fusions
  • Solid tumors with MET amplifications and fusions
Trial Details
Trial Name: APOLLO
Agents: APL-101 (c-Met inhibitor) + APL-501 (anti-PD-1)
Indication: Hepatocellular Carcinoma
Trial: NCT03655613
Trial Details
Trial Name: APOLLO
Agents: APL-101 (c-Met inhibitor) + nivolumab (anti-PD-1)
Indication: Renal Cell Carcinoma
Trial: NCT03655613
Trial Details
Trial Name: APOLLO-2
Agents: APL-101 + APL-103 (EGFR inhibitor)
Indication: TBA

China Partner & Clinical Trials:

Beijing Pearl Biotechnology Co. Ltd. has development rights in China for APL-101 where it is referred to as PLB1001.

Trial Details
Type: Single Agent
Indication: Non-Small Cell Lung Cancer
Trial: NCT04258033

Posters & Publications

Posters and Publications on our assets can be found here.